Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27336148 | 0.77 | KDM4E (0.46) | NOTUMALDH1A1KDM4EBRD4LMNA | |
| SCHEMBL24921501 | 0.74 | KDM4E (0.43) | NOTUMALDH1A1KDM4EBRD4CYP1A2 | |
| SCHEMBL31517328 | 0.73 | ALDH1A1 (0.50) | NOTUMALDH1A1KDM4ECYP1A2LMNA | |
| SCHEMBL6482737 | 0.72 | ALDH1A1 (0.48) | NOTUMALDH1A1KDM4EBRD4LMNA | |
| SCHEMBL22925970 | 0.72 | LMNA (0.57) | NOTUMALDH1A1KDM4ECYP1A2LMNA | |
| SCHEMBL12081541 | 0.72 | LMNA (0.56) | ALDH1A1KDM4EBRD4CYP1A2LMNA | |
| SCHEMBL27547425 | 0.71 | BPTF (0.50) | ALDH1A1CYP1A2LMNABPTFKMT2A | |
| SCHEMBL4328742 | 0.71 | ALDH1A1 (0.47) | NOTUMALDH1A1KDM4EBRD4LMNA | |
| SCHEMBL23560769 | 0.70 | BPTF (0.54) | ALDH1A1KDM4ECYP1A2BPTF | |
| SCHEMBL24240149 | 0.69 | CYP1A2 (0.43) | ALDH1A1CYP1A2LMNABPTFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| EP-3992188-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3950683-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021123291-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021094312-A1 | PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | WO | disclosed |
| CN-107266419-B | Certain amino-pyridazines, compositions thereof, and methods of use thereof | 赛特凯恩蒂克公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| EP-3759106-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Karus Therapeutics Ltd (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| EP-2563365-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-4224325-A | 3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | SLC7A1, F12, C5 | NOTUM 3417/4885ALDH1A1 1962/4885KDM4E 1876/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | NOTUM 3258/4885ALDH1A1 1350/4885KDM4E 581/4885 |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | GABRA5, GABRA3, GABRA2 | NOTUM 2862/4885ALDH1A1 509/4885KDM4E 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.